KRAS and melanoma: The first trial is currently enrolling both NRAS mutant cutaneous melanomas and KRAS or BRAF mutant non-small cell lung cancers progressed after standard of care therapy, while the second one is focused on pre-treated BRAF or NRAS mutant melanomas.